Topical terbinafine in the treatment of cutaneous leishmaniasis: triple blind randomized clinical trial

Journal of Parasitic Diseases

Volumn 40, Issue 4, 2016, Pages 1159-1164

  Farajzadeh, Saeedeh ^a   Heshmatkhah, Amireh ^b   Vares, Behrooz ^b   Mohebbi, Elham ^c   Mohebbi, Azadeh ^b   Aflatoonian, Mahin ^b   Eybpoosh, Sana ^e   Sharifi, Iraj ^a   Aflatoonian, Mohammad Reza ^d   Shamsi Meymandi, Simin ^a   Fekri, Ali Reza ^a   Mostafavi, Mahshid ^a  

^a KERMAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b KERMAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c KERMAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d KERMAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e KERMAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Glucantime; Iran; Kerman; Leishmaniasis; Topical terbinafine

Indexed keywords

MEGLUMINE ANTIMONATE; PLACEBO; TERBINAFINE;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENDER; HUMAN; MAJOR CLINICAL STUDY; MALE; PAPULE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN DEFECT; SKIN LEISHMANIASIS; TREATMENT RESPONSE; YOUNG ADULT;

EID: 84921842459     PISSN: 09717196     EISSN: 09750703     Source Type: Journal    
DOI: 10.1007/s12639-014-0641-1     Document Type: Article

References (20)

1. Aflatoonian MR, Sharifi I, Hakimi Parizi M, Aflatoonian B, Sharifi M, Khosravi A, Fekri AR, Khamesipour A, Sharifi H (2014) A prospective cohort study of cutaneous leishmaniasis risk and opium addiction in South Eastern Iran. PLoS ONE 9(2):e89043
2. Andrade-Neto VV, Cicco NN, Cunha-Junior EF, Canto-Cavalheiro MM, Atella GC, Torres-Santos EC (2011) The pharmacological inhibition of sterol biosynthesis in Leishmania is counteracted by enhancement of LDL endocytosis. Acta Trop 119(2–3):194–198
3. Bahadman KA, Tallab TM (1997) Terbinafin in the treatment of cutaneous leishmaniasis: a pilot study. Int J Dermatol 36:54–60
4. Bahashwan SA (2011) Therapeutic efficacy evaluation of metronidazole and some antifungal agents with meglumine antimoniate on visceral leishmaniasis by real-time light-cycler (LC) PCR in BALB/c mice. Trop J Pharm Res 10(3):255–263
5. Beach DH, Holtz CG, Anchlwe GE (1979) Eipid of leishmania promastigotes. Parasitol 65:203–216
6. Carstens J, Wendelboe P, Sogaard H, Thestrup-Pedersen K (1994) Toxic epidermal necrolysis follow therapy with terhinafine. Acta Derm Venereol (Stockh) 74:391–392
7. Ebrahimian S, Asilian A, Faghihi G (2011) A Comparative study on glucantime and oral terbinafine along with systemic glucantime on cutaneous leishmaniasis. J Isfahan Med Sch 28(118):1246–1252
8. Faergemann J (1997) Pharmacokinetics of terbinafine. Rev Contemp Pharmacother 8:289–297
9. Faergemann J, Zehender H, Jones T, Maibach I (1990) Terbinafine levels in serum, stratum corneum, dermis—epidermis (without stratum corneum), hair, sebum and eccrine sweat. Acta Derm Venereol (Stockh) 71:322–326
10. Gubta S, Jain VK, Aggarwal K (2005) Comparing the efficiency of topical paromomycin with intralesional meglumine antimoniate for cutaneous leishmaniasis. Int J Dermatol 44:1064–1065
11. Kovacs MJ, Al-shammari S, Guenthor L, Bourcier M (1994) Neurotropenia and pancytopenia associated with oral terbinafine. Am Acad Dermatol 31:806
12. Lowe G, Geen C, Jennings R (1993) Hepatitis associated with terbinafine treatment. BMJ 306(6872):248
13. McGregor JM, Rustin MFL (1994) Terbinafine and erythema multiforme. Br J Dermatol 131:587–588
14. Najim RA, Sharquie KE, Farjou IB (1998) Zinc sulphate in the treatment of cutaneous leishmaniasis: an in vitro and animal study. Mem Inst Oswaldo Cruz 93:831–837
15. Ottervanger JP, Stroker BH (1992) Loss of taste and terbinafine. Lancet 340(8821):728
16. Ryder NS (1992) Terbinafine: mode of action and properties of the squalene epoxidase inhibition. Br J Dermatol 39:2–7
17. Ryder NS, Mieth H (1992) Allylamine antifungal drugs. Curr Trop Med My Col 47:158–188
18. Sharifi I, Nakhaei N, Aflatoonian MR, Hakimi Parizi M, Fekri AR, Safizadeh H, Shirzadi MR, Gooya MM, Khamesipour A, Nadim A (2011) Cutaneous leishmaniasis in bam: a comparative evaluation of pre- and post-earthquake years (1999–2008). Iranian J Publ Health 40(2):49–56
19. Sharifi F, Sharifi I, Zarean M, Hakimi Parizi M, Aflatoonian MR, Fasihi Harandi M, Zahmatkesh R, Mashayekhi M, Kermanizadeh AR (2012) Spatial distribution and molecular identification of leishmania species from endemic foci of South-Eastern Iran. Iranian J Parasitol 7(1):45–52
20. Zakai HA, Zimoo SK (2002) Effect of itraconazole and terbinafine on Leishmania major promastigotes. J Kau Med Sci 10:73–80